Comparison

Exenatide vs. Survodutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Exenatide

Exenatide is a 39-amino-acid peptide with about 53% sequence homology to human GLP-1. A glycine substitution at position 2 prevents dipeptidyl-peptidase-IV cleavage and extends the half-life from native GLP-1 (minutes) to about 2.4 hours. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon and delays gastric emptying.

Survodutide

Survodutide is a dual agonist at the GLP-1 and glucagon receptors. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at high blood glucose and modulation of satiety. The glucagon component raises basal energy expenditure via hepatic and brown adipocyte effects. A fatty-acid side chain enables albumin binding and weekly dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Exenatide	Survodutide
Germany	Prescription	Unapproved
JP	—	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Exenatide and Survodutide?: Exenatide is classified as "Metabolic", while Survodutide is classified as "Metabolic". Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Exenatide or Survodutide?: The highest available evidence level is "Human RCT" for Exenatide and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Exenatide and Survodutide in Germany and the United States?: Germany: Exenatide — Prescription, Survodutide — Unapproved. United States: Exenatide — Prescription, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Exenatide

Survodutide

Germany

Prescription

Unapproved

—

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Exenatide and Survodutide?

Exenatide is classified as "Metabolic", while Survodutide is classified as "Metabolic". Exenatide: Synthetic version of exendin-4, originally isolated from the saliva of the Gila monster (Heloderma suspectum). First GLP-1 receptor agonist, FDA-approved 2005 as Byetta. Weekly depot form Bydureon approved 2012. Survodutide: Synthetic peptide that simultaneously activates the GLP-1 and glucagon receptors. Developed by Boehringer Ingelheim and Zealand Pharma; in phase-3 trials for obesity (SYNCHRONIZE) and MASH. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Exenatide or Survodutide?

The highest available evidence level is "Human RCT" for Exenatide and "Human RCT" for Survodutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Exenatide and Survodutide in Germany and the United States?

Germany: Exenatide — Prescription, Survodutide — Unapproved. United States: Exenatide — Prescription, Survodutide — Unapproved. These are factual summaries with source and review date on the individual pages.